The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.
Trigg RM, Lee LC, Prokoph N, Jahangiri L, Reynolds CP, Amos Burke GA, Probst NA, Han M, Matthews JD, Lim HK, Manners E, Martinez S, Pastor J, Blanco-Aparicio C, Merkel O, de Los Fayos Alonso IG, Kodajova P, Tangermann S, Högler S, Luo J, Kenner L, Turner SD.
Trigg RM, et al. Among authors: martinez s.
Nat Commun. 2019 Nov 28;10(1):5428. doi: 10.1038/s41467-019-13315-x.
Nat Commun. 2019.
PMID: 31780656
Free PMC article.